DevCurationThe Premier Voice of the Entire Tech Ecosystem
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Latest
Onward Therapeutics Discloses $28M Series B for Oncology|MountAIn Raises €7.3M Seed for Edge AI Deployment|Previsia Raises €3.8M Seed to Expand AI Risk Prevention|ROTOBOOST Takes Aramco Investment for Hydrogen and Carbon|Commit Biologics’ $60M Seed Backs Complement Immune Engagers|Perry AI Raises $2.2M Seed for Private Capital Legal Work|ODAIA Raises $15M Series C for Pharma Commercial Intelligence|Mulga Raises US$1.77M Pre-Seed for AWS-Compatible Cloud|FluidCloud Takes Singular Link Investment for Saudi Expansion|Kernal Bio Secures IFLI Investment for In Vivo CAR-T Work|Onward Therapeutics Discloses $28M Series B for Oncology|MountAIn Raises €7.3M Seed for Edge AI Deployment|Previsia Raises €3.8M Seed to Expand AI Risk Prevention|ROTOBOOST Takes Aramco Investment for Hydrogen and Carbon|Commit Biologics’ $60M Seed Backs Complement Immune Engagers|Perry AI Raises $2.2M Seed for Private Capital Legal Work|ODAIA Raises $15M Series C for Pharma Commercial Intelligence|Mulga Raises US$1.77M Pre-Seed for AWS-Compatible Cloud|FluidCloud Takes Singular Link Investment for Saudi Expansion|Kernal Bio Secures IFLI Investment for In Vivo CAR-T Work
DevCuration

The premier voice of the tech ecosystem, from ideation to enterprise.

Explore

  • Where the Money Moved
  • Events
  • Articles & Analysis

Spotlights

  • Investor Spotlight
  • Company Spotlight
  • Frameworks

Company

  • About Us
  • Privacy Policy
  • Terms of Service
© 2026 DevCuration. All rights reserved.
TwitterLinkedIn
Logos provided by Logo.dev
Back to articles
November 20, 2026
•Jesse LandryJesse Landry

Commit Biologics’ $60M Seed Backs Complement Immune Engagers

Four scientists kept working on complement recruitment after their regular university jobs were done. Commit Biologics, the company that grew from that work at Aarhus University, is now putting $60M in total Seed financing behind a defined development program and the organization needed to bring it toward patients. The Danish biotech operates in Aarhus and Copenhagen, with COM002 becoming the first candidate around which that clinical work is being assembled.

Commit announced the final close on November 17, 2026, led by Ackermans & van Haaren, with new investors AbbVie Ventures and M Ventures joining Bioqube Ventures, Korys and Novo Holdings. The financing supports COM002’s IND-enabling studies and filing, a second program and the wider pipeline. Its significance for immunotherapy is the biological resource Commit wants to recruit: complement proteins, with a mechanism designed to work independently of T-cell function. First patient dosing is a company expectation for early 2028; the development work remains preclinical.

What Commit Biologics’ $60M Seed financing covers

The seed label spans several chapters of Commit’s development. The company emerged from stealth in May 2024 with €16M from Bioqube Ventures and Novo Holdings, then announced a €5.5M Korys extension in January 2025. That extension brought the seed total to €21.5M. The latest announcement describes a final total of $60M, reported by Commit as €54M. Earlier seed disclosures belong in that financing history rather than being added again to the November figure.

The lead investor’s own terms add useful detail. Through AvH Growth Capital, Ackermans & van Haaren committed up to €10.5M in conditional tranches, with an initial 10.2% shareholding. Those commitments sit within the financing, and the release does not establish that every tranche has already arrived in Commit’s bank account. A final round total and a particular investor’s staged funding describe different parts of the same transaction.

That distinction matters when reading the clinical plan. Commit is financing a sequence of development activities: preparing COM002 for an IND application, moving another program toward IND-enabling work and broadening the platform pipeline. The new board representatives include Michael Rosenzweig of AbbVie Ventures, Charlotte Kremers of M Ventures and Lenny Van Steenhuyse of Ackermans & van Haaren. Scientific prioritization and capital allocation will meet repeatedly as the company turns that program list into funded studies.

How BiCE recruits a different immune resource

Commit’s Bispecific Complement Engager platform combines recognition of a selected cell with recruitment of C1q, a protein involved in starting the classical complement pathway. In the company’s description, the engineered antibody brings C1q to the target-cell surface, where complement activation can help eliminate that cell. The approach is intended to put a specific immune mechanism at the disposal of the drug designer.

The dependency is important. T-cell-directed therapies need functional cellular participants; Commit is developing a route that recruits complement instead. That gives its researchers a different starting point for diseases in which T-cell fitness or access can be limiting. It also creates a demanding development question: how selectively can that immune activity be directed in the setting where a future medicine would actually be used?

The distinction should stay biological rather than become a ranking of therapies. DevCuration’s coverage of T-Therapeutics’ T-cell-receptor development offers an adjacent example of a different immune approach moving toward clinical work. Commit’s mechanism and its intended antibody formats offer a development proposition, while clinical comparisons require evidence in patients. The company has reported platform proof of concept in non-human primates, including targeted B-cell depletion. Those observations describe preclinical research, and the safety and activity of COM002 in people remain questions for its clinical development.

For operators following immune-engager businesses, the useful unit of analysis is the dependency each design carries. Commit is choosing complement recruitment as the engine behind targeted cell depletion. Its opportunity therefore involves both finding suitable targets and learning how the recruited immune machinery behaves around them, across the conditions the company eventually proposes to treat.

From four academic founders to a clinical organization

Commit’s origins sit with Aarhus University researchers Dennis Vestergaard Pedersen, Nick Stub Laursen, Mikael Becher Lykkegaard Winkler and Heidi Gytz Olesen. The university’s account of the spinout identifies all four founders, while original research records document their work on complement recruitment. That history establishes the scientific roots without turning the founders’ earlier operating titles into a claim about today’s organization.

The current leadership structure reflects the stage of work ahead. Thomas L. F. Montgomery Andresen became CEO in March 2026, and Mikkel Wandahl Pedersen remains CSO after previously serving as interim CEO. Alongside the nomination of COM002, Commit appointed Anne-Marie Levy Rasmussen as COO and Wolthers as clinical-development head. The responsibilities extend from building the organization to preparing studies and navigating the regulatory process.

That is a substantive change in what a platform company needs to coordinate. Discovery can keep generating possible applications while a development candidate demands decisions about a particular population, study sequence and clinical plan. Commit now has leaders assigned to connect those decisions, with a candidate nomination and financing arriving within the same week.

For the founding scientists, the invention is entering an organization with a broader set of obligations. Scientific work continues, but it must increasingly arrive in forms that development and clinical teams can use. The new hires make that organizational handoff visible, giving the financing a human consequence alongside its laboratory ambitions.

COM002’s initial indication gives the platform a destination

Commit nominated COM002 on November 12 as its first development candidate. Its announced initial focus is relapsed or refractory non-Hodgkin lymphoma, with plans to expand into autoimmune indications. The lead investor describes a dual-targeting molecule intended to deplete B cells and T follicular helper cells. These are development intentions, and the company’s early-2028 dosing expectation remains prospective.

The initial indication gives the broader platform story a narrower assignment. Researchers can describe multiple disease areas in which complement recruitment might be useful, while the clinical team must prepare a plan for an identifiable patient population. A second program advancing toward IND-enabling work adds another set of choices about where the platform should go after COM002.

The financing brings new financial and strategic investors into that process alongside the existing backers. Their participation supports continued development, while the candidate and leadership appointments show where Commit intends to put the work. For a reader assessing the business, the most concrete progress markers are now embedded in the clinical preparation rather than in the size of the platform’s theoretical reach.

Wolthers’ remit carries the biology into study design, translational planning and regulatory work. As Commit prepares COM002 for its proposed first patients, those teams will have to connect the cell-depletion mechanism with the specific lymphoma setting the company has chosen to enter. The complement platform now has a clinical itinerary being assembled around it.

Frequently Asked Questions

How does BiCE differ from a T-cell-directed immune engager?

Commit’s BiCE platform is designed to recruit the complement protein C1q to selected cells. Its intended cell-depletion mechanism works independently of T-cell function; clinical advantages over other approaches have not been established.

What development work does the seed financing support?

The $60M total seed financing supports COM002 IND-enabling activities and an IND filing, a second program moving into IND-enabling development and pipeline expansion. The announced first-patient dosing expectation is early 2028, rather than a completed clinical milestone.

Does the $60M figure represent a wholly new round on top of earlier seed funding?

Commit describes $60M as the final seed-financing total. Earlier disclosed seed amounts belong in that financing history and should not be added again; Ackermans & van Haaren’s conditional tranches are part of its participation in the financing.

Why is Commit starting COM002 development in lymphoma?

Commit identifies relapsed or refractory non-Hodgkin lymphoma as its planned initial development setting, with autoimmune expansion intended later. COM002 is a dual-targeting immune-cell-depletion candidate; the initial patient focus gives the clinical team a defined program to prepare.

What has Commit established about activity in patients?

The announcements describe preclinical platform data and preparations for clinical development. They do not establish COM002 efficacy or safety in patients, and the dosing timeline remains the company’s expectation.

Back to all articles
Newsletter

Where the Money Moved

The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.

Subscribe to Where the Money Moved
Commit Biologics

Commit Biologics

  • Aarhus and Copenhagen, Denmark
WebsiteLinkedIn

Key Executives

  • Thomas L. F. Montgomery Andresen
  • Mikkel Wandahl Pedersen
+2 more (coming soon)

Investors

Ackermans & van Haaren
View Career Page

Related Articles

Funding Announcement
MountAIn Raises €7.3M Seed for Edge AI Deployment
Nov 20, 2026
Funding Announcement
Previsia Raises €3.8M Seed to Expand AI Risk Prevention
Nov 20, 2026
Funding Announcement
Perry AI Raises $2.2M Seed for Private Capital Legal Work
Nov 20, 2026
Funding Announcement
Global Kiwi Labs Raises $4M Seed for TheHUB Expansion
Nov 20, 2026
Funding Announcement
AstraNu Closes $3.5M Seed for Chip-Scale OCT Imaging
Nov 20, 2026

Trending

Events
Alumni Ventures Examines Voice AI’s Business Case on Nov. 19
Nov 18, 2026
News
Serve Robotics Opens Physical AI Services to Outside Fleets
Nov 15, 2026
View all posts